Resveratrol inhibits 11β-hydroxysteroid dehydrogenase type 1 activity in rat adipose microsomes

Journal of Endocrinology

Volumn 218, Issue 3, 2013, Pages 311-320

  Tagawa, Noriko ^a   Kubota, Sayaka ^a   Kato, Ikuo ^a   Kobayashi, Yoshiharu ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

11 HSD1; Adipocyte; Antiobesity effect; Resveratrol

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; DEHYDROCORTICOSTERONE; GLUCOCORTICOID; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; RESVERATROL;

ADIPOCYTE; ADIPOSE MICROSOME; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; EPIDIDYMIS; IC 50; MALE; MESENTERY; MICROSOME; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

11Β-HSD1; ADIPOCYTE; ANTIOBESITY EFFECT; RESVERATROL;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3T3 CELLS; ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; DOWN-REGULATION; KINETICS; MALE; MICE; MICROSOMES; RATS; RATS, WISTAR; STILBENES;

EID: 84884171123     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0066     Document Type: Article

References (38)

1. Albiston AL, Obeyesekere VR, Smith RE & Krozowski ZS 1994 Cloning and tissue distribution of the human 11b-hydroxysteroid dehydrogenase type 2 enzyme. Molecular and Cellular Endocrinology 105:R11-R17. (doi:10.1016/0303-7207(94)90176-7)
2. Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, & Mikhailidis DP 2013 11b-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 62:21-33. (doi:10.1016/ j.metabol.2012.05.002)
3. Andrews RC, Rooyackers O, & Walker BR 2003 Effects of the 11b-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88:285-291. (doi:10.1210/jc.2002- 021194)
4. Atanasov AG, Nashev LG, Schweizer RA, Frick C, & Odermatt A 2004 Hexose-6-phosphate dehydrogenase determines the reaction direction of 11b-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Letters 571:129-133. (doi:10.1016/j.febslet. 2004.06.065)
5. Baile CA, Yang JY, Rayalam S, Hartzell DL, Lai CY, Andersen C, & Della-Fera MA 2011 Effect of resveratrol on fat mobilization. Annals of the New York Academy of Sciences 1215:40-47. (doi:10.1111/j.1749-6632. 2010.05845.x)
6. Bowers JL, Tyulmenkov VV, Jernigan SC, & Klinge CM 2000 Resveratrol acts as a mixed agonist/antagonist for estrogen receptors a and b. Endocrinology 141 3657-3667. (doi:10.1210/en.141.10.3657)
7. Boyle CD 2008 Recent advances in the discovery of 11b-HSD1 inhibitors. Current Opinion in Drug Discovery, & Development 11:495-511.
8. Bujalska IJ, Kumar S, & Stewart PM 1997 Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349:1210-1213. (doi:10.1016/S0140-6736(96)11222-8)
9. Chachay VS, Kirkpatrick CM, Hickman IJ, Ferguson M, Prins JB, & Martin JH 2011 Resveratrol - pills to replace a healthy diet? British Journal of Clinical Pharmacology 72:27-38. (doi:10.1111/j.1365-2125.2011.03966.x)
10. Chou JY, Matern D, Mansfield BC, & Chen YT 2002 Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Current Molecular Medicine 2:121-143. (doi:10.2174/1566524024605798)
11. Dixon M 1953 The determination of enzyme inhibitor constants. Biochemical Journal 55:170-171.
12. Evinger AJ, & Levin ER 2005 Requirements for estrogen receptor a membrane localization and function. Steroids 70:361-363. (doi:10.1016/j.steroids.2005.02.015)
13. Feng Y, Huang SL, Dou W, Zhang S, Chen JH, Shen Y, Shen JH, & Leng Y 2010 Emodin, a natural product, selectively inhibits 11b-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. British Journal of Pharmacology 161:113-126. (doi:10.1111/j.1476-5381.2010.00826.x)
14. Ge RS, Gao HB, Nacharaju VL, Gunsalus GL, & Hardy MP 1997 Identification of a kinetically distinct activity of 11b-hydroxysteroid dehydrogenase in rat Leydig cells. Endocrinology 138:2435-2442. (doi:10.1210/en.138.6.2435)
15. Hewitt KN, Walker EA, & Stewart PM2005Minireview: hexose-6-phosphate dehydrogenase and redox control of 11b-hydroxysteroid dehydrogenase type 1 activity. Endocrinology 146:2539-2543. (doi:10.1210/en. 2005-0117)
16. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL et al. 2003 Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191-196. (doi:10.1038/nature1960)
17. Kannisto K, Pietilainen KH, Ehrenborg E, Rissanen A, Kaprio J, Hamsten A, & Yki-Jarvinen H 2004 Overexpression of 11b-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. Journal of Clinical Endocrinology and Metabolism 89:4414-4421. (doi:10.1210/jc.2004-0153)
18. Kiyonaga D, Tagawa N, Yamaguchi Y, Wakabayashi M, Kogure T, Ueda M, Miyata O, & Kobayashi Y 2012 Benzofuran derivatives inhibit 11b-hydroxysteroid dehydrogenase type 1 activity in rat adipose tissue. Biological, & Pharmaceutical Bulletin 35:1275-1280. (doi:10.1248/bpb. b12-00072)
19. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR et al. 1997 11b-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoidinducible responses and resist hyperglycemia on obesity or stress. PNAS 94:14924-14929. (doi:10.1073/pnas.94.26.14924)
20. Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CH, Parker KL, White PC, & Stewart PM 2006 Hexose-6-phosphate dehydrogenase knock-out mice lack 11b-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. Journal of Biological Chemistry 281:6546-6551. (doi:10.1074/jbc.M512635200)
21. Livingstone DE, & Walker BR 2003 Is 11b-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats Journal of Pharmacology and Experimental Therapeutics 305:167-172. (doi:10.1124/jpet.102.044842)
22. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, & Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170. (doi:10.1126/science.1066285)
23. McCormick KL, Wang X, & Mick GJ 2006 Evidence that the 11b-hydroxysteroid dehydrogenase (11b-HSD1) is regulated by pentose pathway flux. Studies in rat adipocytes and microsomes. Journal of Biological Chemistry 281:341-347. (doi:10.1074/jbc.M506026200)
24. Mercer WR, & Krozowski ZS 1992 Localization of an 11b hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney. Endocrinology 130:540-543. (doi:10.1210/en.130.1.540)
25. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB et al. 2007 Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716. (doi:10.1038/nature06261)
26. Pappas TC, Gametchu B, & Watson CS 1995 Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB Journal 9:404-410.
27. Pereira CD, Azevedo I, Monteiro R, & Martins MJ 2012 11b-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes, Obesity, & Metabolism 14:869-881. (doi:10.1111/ j.1463-1326.2012.01582.x)
28. Petrovski G, Gurusamy N, & Das DK 2011 Resveratrol in cardiovascular health and disease. Annals of the New York Academy of Sciences 1215:22-33. (doi:10.1111/j.1749-6632.2010.05843.x)
29. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, & Guarente L 2004 Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-g. Nature 429:771-776. (doi:10.1038/nature02583)
30. Razandi M, Pedram A, Greene GL, & Levin ER 1999 Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERa and ERb expressed in Chinese hamster ovary cells. Molecular Endocrinology 13:307-319. (doi:10.1210/me.13.2.307)
31. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, & Prossnitz ER 2005 A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625-1630. (doi:10.1126/science.1106943)
32. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, & Walker BR 2005 Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11b-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54:872-879. (doi:10.2337/diabetes. 54.3.872)
33. Smoliga JM, Baur JA, & Hausenblas HA 2011 Resveratrol and health - a comprehensive review of human clinical trials. Molecular Nutrition, & Food Research 55:1129-1141. (doi:10.1002/mnfr.201100143)
34. Szkudelska K, & Szkudelski T 2010 Resveratrol, obesity and diabetes. European Journal of Pharmacology 635:1-8. (doi:10.1016/j.ejphar.2010. 02.054)
35. Tagawa N, Yuda R, Kubota S, Wakabayashi M, Yamaguchi Y, Kiyonaga D, Mori N, Minamitani E, Masuzaki H, & Kobayashi Y 2009 17b-Estradiol inhibits 11b-hydroxysteroid dehydrogenase type 1 activity in rodent adipocytes. Journal of Endocrinology 202:131-139. (doi:10.1677/JOE- 09-0021)
36. Taylor A, Irwin N, McKillop AM, Flatt PR, & Gault VA 2008 Sub-chronic administration of the 11b-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity. Biological Chemistry 389:441-445. (doi:10.1515/BC.2008.049)
37. Turan B, Tuncay E, & Vassort G 2012 Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. Journal of Bioenergetics and Biomembranes 44:281-296. (doi:10.1007/s10863-012- 9429-0)
38. Voet D, & Voet JG 2004 In Inhibition in Biochemistry, 3rd edn, pp 482-486. Eds D Voet, & JG Voet. New York: J. Wiley, & Sons, Inc. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, & Walker BR 2003 Local and systemic impact of transcriptional up-regulation of 11b-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. Journal of Clinical Endocrinology and Metabolism 88:3983-3988. (doi:10.1210/jc.2003-030286)